MRNA · 10-Q · 2026Q3 · Full report

Patent Infringement Lawsuit

Moderna, Inc. · 2026-11-06 · Importance 47 · Surprise 60

Moderna and Pfizer/BioNTech have brought patent actions or asserted challenges concerning Moderna’s mRNA platform technology and vaccine designs in the United States, Germany, the Netherlands, the UK, Ireland, and Belgium. In September 2026, the European Patent Office’s Technical Board of Appeal revoked Moderna’s European Patent No. 3 590 949; related proceedings in Belgium, Ireland, and the Netherlands were dismissed, while proceedings in Germany and the UK remained pending. Moderna also asserted a European patent against Pfizer and BioNTech in the Unified Patent Court, and multiple companies and universities have filed patent complaints against Moderna in U.S. and European courts. The filing does not quantify potential financial exposure from these proceedings.